Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2026 13:14 ET | Source: Robbins LLP

Robbins LLP Urges RARE Stockholders to Contact the Firm for Information About the Class Action Against Ultragenyx Pharmaceutical Inc.

Robbins LLP is Investigating Allegations that Ultragenyx Pharmaceutical Inc. (RARE) Misled Investors Regarding Phase III Orbit and Cosmic Studies
February 18, 2026 14:07 ET | Source: Robbins LLP

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Robbins LLP is Investigating Allegations that Ultragenyx Pharmaceutical Inc. (RARE) Misled Investors Regarding Phase III Orbit and Cosmic Studies
February 09, 2026 16:06 ET | Source: Robbins LLP

RARE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ultragenyx Pharmaceutical Inc. Class Action

Robbins LLP is investigating claims that Ultragenyx (RARE) misled investors about Phase III Orbit and Cosmic trials for setrusumab.